MYC and medulloblastoma: Finally, another unique contribution of this work is the establishment and characterization of a pair of low-passage pediatric medulloblastoma cell lines from the original tumor (MYC amplified Group 4 medulloblastoma) and from its recurrence in the same patient, in which the germline BRCA2 6174delT mutation may have predisposed to the medulloblastoma.